Triptych Biotherapeutics

Triptych Biotherapeutics is a pre-clinical stage biotechnology company focused on developing next-generation multi-specific antibodies for oncology. The company's platform specializes in the engineering of trispecific T-cell engagers designed to improve the therapeutic index and efficacy compared to traditional bispecific formats. By targeting multiple antigens or utilizing conditional activation mechanisms, Triptych aims to treat complex solid tumors and hematological cancers that are often resistant to current immunotherapies. Headquartered in Cambridge, Massachusetts, the firm is led by experienced executives from the cell therapy and biologics sectors. Triptych is currently leveraging its protein engineering expertise to advance a pipeline of candidates toward the clinic.